The clinical utility of lung clearance index in early cystic fibrosis lung disease is not impacted by the number of multiple-breath washout trials

Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF)

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The lung clearance index (LCI) from the multiple-breath washout (MBW) test is a promising surveillance tool for pre-school children with cystic fibrosis (CF). Current guidelines for MBW testing recommend that three acceptable trials are required. However, success rates to achieve these criteria are low in children aged <7 years and feasibility may improve with modified pre-school criteria that accepts tests with two acceptable trials. This study aimed to determine if relationships between LCI and clinical outcomes of CF lung disease differ when only two acceptable MBW trials are assessed. Healthy children and children with CF aged 3–6 years were recruited for MBW testing. Children with CF also underwent bronchoalveolar lavage fluid collection and a chest computed tomography scan. MBW feasibility increased from 46% to 75% when tests with two trials were deemed acceptable compared with tests where three acceptable trials were required. Relationships between MBW outcomes and markers of pulmonary inflammation, infection and structural lung disease were not different between tests with three acceptable trials compared with tests with two acceptable trials. This study indicates that pre-school MBW data from two acceptable trials may provide sufficient information on ventilation distribution if three acceptable trials are not possible.

Original languageEnglish (US)
Article number00094-2017
JournalERS Monograph
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Cystic Fibrosis
Lung Diseases
Lung
Breath Tests
Bronchoalveolar Lavage Fluid
Ventilation
Pneumonia
Thorax
Tomography
Guidelines
Infection

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The clinical utility of lung clearance index in early cystic fibrosis lung disease is not impacted by the number of multiple-breath washout trials. / Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF).

In: ERS Monograph, Vol. 4, No. 1, 00094-2017, 01.01.2018.

Research output: Contribution to journalArticle

Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF). / The clinical utility of lung clearance index in early cystic fibrosis lung disease is not impacted by the number of multiple-breath washout trials. In: ERS Monograph. 2018 ; Vol. 4, No. 1.
@article{7da38909ed0d4103b8e09ec879d0474f,
title = "The clinical utility of lung clearance index in early cystic fibrosis lung disease is not impacted by the number of multiple-breath washout trials",
abstract = "The lung clearance index (LCI) from the multiple-breath washout (MBW) test is a promising surveillance tool for pre-school children with cystic fibrosis (CF). Current guidelines for MBW testing recommend that three acceptable trials are required. However, success rates to achieve these criteria are low in children aged <7 years and feasibility may improve with modified pre-school criteria that accepts tests with two acceptable trials. This study aimed to determine if relationships between LCI and clinical outcomes of CF lung disease differ when only two acceptable MBW trials are assessed. Healthy children and children with CF aged 3–6 years were recruited for MBW testing. Children with CF also underwent bronchoalveolar lavage fluid collection and a chest computed tomography scan. MBW feasibility increased from 46{\%} to 75{\%} when tests with two trials were deemed acceptable compared with tests where three acceptable trials were required. Relationships between MBW outcomes and markers of pulmonary inflammation, infection and structural lung disease were not different between tests with three acceptable trials compared with tests with two acceptable trials. This study indicates that pre-school MBW data from two acceptable trials may provide sufficient information on ventilation distribution if three acceptable trials are not possible.",
author = "{Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF)} and Foong, {Rachel E.} and Harper, {Alana J.} and Billy Skoric and Louise King and Lidija Turkovic and Miriam Davis and Clem, {Charles C.} and Tim Rosenow and Stephanie Davis and Sarath Ranganathan and Hall, {Graham L.} and Ramsey, {Kathryn A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1183/23120541.00094-2017",
language = "English (US)",
volume = "4",
journal = "ERS Monograph",
issn = "2312-508X",
publisher = "European Respiratory Society",
number = "1",

}

TY - JOUR

T1 - The clinical utility of lung clearance index in early cystic fibrosis lung disease is not impacted by the number of multiple-breath washout trials

AU - Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF)

AU - Foong, Rachel E.

AU - Harper, Alana J.

AU - Skoric, Billy

AU - King, Louise

AU - Turkovic, Lidija

AU - Davis, Miriam

AU - Clem, Charles C.

AU - Rosenow, Tim

AU - Davis, Stephanie

AU - Ranganathan, Sarath

AU - Hall, Graham L.

AU - Ramsey, Kathryn A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The lung clearance index (LCI) from the multiple-breath washout (MBW) test is a promising surveillance tool for pre-school children with cystic fibrosis (CF). Current guidelines for MBW testing recommend that three acceptable trials are required. However, success rates to achieve these criteria are low in children aged <7 years and feasibility may improve with modified pre-school criteria that accepts tests with two acceptable trials. This study aimed to determine if relationships between LCI and clinical outcomes of CF lung disease differ when only two acceptable MBW trials are assessed. Healthy children and children with CF aged 3–6 years were recruited for MBW testing. Children with CF also underwent bronchoalveolar lavage fluid collection and a chest computed tomography scan. MBW feasibility increased from 46% to 75% when tests with two trials were deemed acceptable compared with tests where three acceptable trials were required. Relationships between MBW outcomes and markers of pulmonary inflammation, infection and structural lung disease were not different between tests with three acceptable trials compared with tests with two acceptable trials. This study indicates that pre-school MBW data from two acceptable trials may provide sufficient information on ventilation distribution if three acceptable trials are not possible.

AB - The lung clearance index (LCI) from the multiple-breath washout (MBW) test is a promising surveillance tool for pre-school children with cystic fibrosis (CF). Current guidelines for MBW testing recommend that three acceptable trials are required. However, success rates to achieve these criteria are low in children aged <7 years and feasibility may improve with modified pre-school criteria that accepts tests with two acceptable trials. This study aimed to determine if relationships between LCI and clinical outcomes of CF lung disease differ when only two acceptable MBW trials are assessed. Healthy children and children with CF aged 3–6 years were recruited for MBW testing. Children with CF also underwent bronchoalveolar lavage fluid collection and a chest computed tomography scan. MBW feasibility increased from 46% to 75% when tests with two trials were deemed acceptable compared with tests where three acceptable trials were required. Relationships between MBW outcomes and markers of pulmonary inflammation, infection and structural lung disease were not different between tests with three acceptable trials compared with tests with two acceptable trials. This study indicates that pre-school MBW data from two acceptable trials may provide sufficient information on ventilation distribution if three acceptable trials are not possible.

UR - http://www.scopus.com/inward/record.url?scp=85042796737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042796737&partnerID=8YFLogxK

U2 - 10.1183/23120541.00094-2017

DO - 10.1183/23120541.00094-2017

M3 - Article

AN - SCOPUS:85042796737

VL - 4

JO - ERS Monograph

JF - ERS Monograph

SN - 2312-508X

IS - 1

M1 - 00094-2017

ER -